MSN Labs has entered into a royalty-free, non-exclusive, voluntary license agreement with the US-based Eli Lilly and Co for manufacturing and marketing of baricitinib in India.
The drug baricitinib has been granted a restricted emergency use approval in India by the Central Drugs Standard Control Organization for emergency use in combination with remdesivir for the treatment of suspected or laboratory confirmed Covid-19 in hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
“This collaboration with Eli Lilly and Co is a landmark milestone in India’s fight against Covid-19 and will thus help in increasing the availability and affordability of baricitinib,'' MSN Reddy, CMD – MSN Group said in a release on Thursday.
Hyderabad-based MSN will be launching the product under the brand name BARIDOZ in two strengths-2 mg and 4mg. MSN has developed the active pharmaceutical ingredient and the formulation of baricitinib in its in-house R&D and manufacturing units.
As part of the Covid treatment range, MSN has already launched Favilow (Favipiravir) and Oselow (Oseltamivir).
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.